These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22876919)

  • 61. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.
    Lara-Castro C; Fu Y; Chung BH; Garvey WT
    Curr Opin Lipidol; 2007 Jun; 18(3):263-70. PubMed ID: 17495599
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Influence of visceral obesity on the secretion of adipokines with epicardial adipocytes in patients with coronary heart disease.
    Gruzdeva OV; Borodkina AD; Akbasheva OE; Dileva YA; Antonova LV; Matveeva VG; Uchasova EG; Ivanov SV; Belik EV; Fanaskova EV; Karetnikova VN; Kokov AN; Barbarash OL
    Ter Arkh; 2018 Nov; 90(10):71-78. PubMed ID: 30701799
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The metabolic syndrome: metabolic changes with vascular consequences.
    Wassink AM; Olijhoek JK; Visseren FL
    Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
    Goto T; Teraminami A; Lee JY; Ohyama K; Funakoshi K; Kim YI; Hirai S; Uemura T; Yu R; Takahashi N; Kawada T
    J Nutr Biochem; 2012 Jul; 23(7):768-76. PubMed ID: 21889885
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adiponectin, lipids and atherosclerosis.
    Katsiki N; Mantzoros C; Mikhailidis DP
    Curr Opin Lipidol; 2017 Aug; 28(4):347-354. PubMed ID: 28463859
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protective role of adiponectin in cardiovascular disease.
    Shibata R; Murohara T; Ouchi N
    Curr Med Chem; 2012; 19(32):5459-66. PubMed ID: 22876923
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adiponectin--a key adipokine in the metabolic syndrome.
    Whitehead JP; Richards AA; Hickman IJ; Macdonald GA; Prins JB
    Diabetes Obes Metab; 2006 May; 8(3):264-80. PubMed ID: 16634986
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Systemic adiponectin malfunction as a risk factor for cardiovascular disease.
    Lau WB; Tao L; Wang Y; Li R; Ma XL
    Antioxid Redox Signal; 2011 Oct; 15(7):1863-73. PubMed ID: 21091079
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pulmonary Hypertension and Obesity: Focus on Adiponectin.
    Perrotta F; Nigro E; Mollica M; Costigliola A; D'Agnano V; Daniele A; Bianco A; Guerra G
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791536
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adipokines at the crossroad between obesity and cardiovascular disease.
    Molica F; Morel S; Kwak BR; Rohner-Jeanrenaud F; Steffens S
    Thromb Haemost; 2015 Mar; 113(3):553-66. PubMed ID: 25338625
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adipocytokines and the metabolic complications of obesity.
    Rasouli N; Kern PA
    J Clin Endocrinol Metab; 2008 Nov; 93(11 Suppl 1):S64-73. PubMed ID: 18987272
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Adiponectin, obesity, and cardiovascular disease.
    Fasshauer M; Paschke R; Stumvoll M
    Biochimie; 2004 Nov; 86(11):779-84. PubMed ID: 15589686
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adiponectin: anti-inflammatory and cardioprotective effects.
    Villarreal-Molina MT; Antuna-Puente B
    Biochimie; 2012 Oct; 94(10):2143-9. PubMed ID: 22796520
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adiponectin--its role in metabolism and beyond.
    Stefan N; Stumvoll M
    Horm Metab Res; 2002 Sep; 34(9):469-74. PubMed ID: 12384822
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Adiponectin: an anti-carcinogenic adipokine?].
    Fève B
    Ann Endocrinol (Paris); 2013 May; 74(2):102-5. PubMed ID: 23570813
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adiponectin: An Endothelium-Derived Vasoprotective Factor?
    Shen L; Evans IM; Souza D; Dreifaldt M; Dashwood MR; Vidya MA
    Curr Vasc Pharmacol; 2016; 14(2):168-74. PubMed ID: 26638793
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease.
    Gable DR; Hurel SJ; Humphries SE
    Atherosclerosis; 2006 Oct; 188(2):231-44. PubMed ID: 16581078
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of the new C1q/TNF-related protein (CTRP-3) "cartonectin" on the adipocytic secretion of adipokines.
    Wölfing B; Buechler C; Weigert J; Neumeier M; Aslanidis C; Schöelmerich J; Schäffler A
    Obesity (Silver Spring); 2008 Jul; 16(7):1481-6. PubMed ID: 18421280
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hypoadiponectinemia as a marker of adipocyte dysfunction--part II: the functional significance of low adiponectin secretion.
    Stern N; Osher E; Greenman Y
    J Cardiometab Syndr; 2007; 2(4):288-94. PubMed ID: 18059213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.